Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00671658 · ClinicalTrials.gov registry record · Phase 2
Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
NCT00671658: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00671658 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 220 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00671658, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if intensive chemotherapy (with monoclonal antibody therapy in some patients) given for 8 courses over 5 to 6 months followed by monthly maintenance chemotherapy for 2 ½ years can improve or cure acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma.
Primary Outcome
Response - Complete remission (CR): Normalization peripheral blood \& bone marrow 5% or \<blasts in normocellular or hypercellular marrow granulocyte count of 1x10\^9/L or \> \& platelet count \>100x10\^9/L; CR with incomplete platelet recovery (CRp): CR but platelet count \<100x10\^9/L. CR with incomplete recovery (CRi): CR but platelet count \<100x10\^9/L or absolute neutrophil count \< 1x10\^9/L. Partial response (PR): As above except for presence of 6-25% marrow blasts. Lymphoblastic lymphom
Interventions
- DRUG Doxorubicin
- DRUG Rituximab
- DRUG Dexamethasone
- DRUG Vincristine
- DRUG Cyclophosphamide (CTX)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2002-11 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
What the finished NCT00671658 record still lists
NCT00671658 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% higher).
The record links to 0 conditions, and to 5 interventions - of which Doxorubicin is the first listed.
NCT00671658 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00671658 about?
NCT00671658 is a clinical study titled "Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia". The goal of this clinical research study is to learn if intensive chemotherapy (with monoclonal antibody therapy in some patients) given for 8 courses over 5 to 6 months followed by monthly maintenance chemotherapy for 2 ½ years can improve or cure acute lymphoblastic leukemia (ALL) or lymphoblastic...
What is the current status of trial NCT00671658?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2002-11. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00671658?
The interventions under investigation include: Doxorubicin (DRUG), Rituximab (DRUG), Dexamethasone (DRUG), Vincristine (DRUG), Cyclophosphamide (CTX) (DRUG).
Who is sponsoring clinical trial NCT00671658?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00671658's enrollment target sits among peer trials
220 275th of 2000 higher than 1,718 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia